SCHEMBL4397933

SCHEMBL4397933

Cc1cnccc1OCC(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 6/20 0.51
SSTR4 P31391 3/20 0.44
GSK3B P49841 6/20 0.41
MAPT P10636 2/20 0.41
PDE2A O00408 1/20 0.41
PDE10A Q9Y233 1/20 0.41
GSK3A P49840 6/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
THRB P10828 1/20 0.39
G6PD P11413 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28160859 0.86 CYP17A1 (0.51) CYP17A1SSTR4GSK3BMAPTPDE2A
Ammonia Solution, Strong SCHEMBL28408262 0.84 CYP17A1 (0.50) CYP17A1SSTR4GSK3BMAPTPDE2A
SCHEMBL15733041 0.79 CYP17A1 (0.42) CYP17A1SSTR4GSK3BMAPTGSK3A
SCHEMBL15791321 0.79 MAPT (0.52) CYP17A1GSK3BMAPTGSK3AKDM4E
SCHEMBL4079147 0.77 CA12 (0.54) SSTR4MEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL4076045 0.76 PDE10A (0.40) CYP17A1SSTR4PDE2APDE10ACYP1A2
SCHEMBL17610600 0.75 CYP17A1 (0.40) CYP17A1SSTR4GSK3BMAPTGSK3A
SCHEMBL28151932 0.75 CYP17A1 (0.45) CYP17A1SSTR4GSK3BMAPTGSK3A
SCHEMBL29530887 0.75 GSK3B (0.43) CYP17A1GSK3BMAPTGSK3AKDM4E
SCHEMBL4070510 0.74 PDE5A (0.40) SSTR4MAPTKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104257680-A Pill for eradicating helicobacter pylori WANG DEPU 2015-01-07 CN claimed
EP-2308492-B1 Process for preparing lansoprazole KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) 2016-09-14 EP disclosed
CN-103202820-B A kind of stable lansoprazole intestine dissolving capsule and preparation method thereof Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) 2016-03-30 CN disclosed
CN-103271884-B Lansoprazole composition and preparation method thereof YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. (CN) 2015-12-09 CN disclosed
CN-104257680-A Pill for eradicating helicobacter pylori WANG DEPU 2015-01-07 CN disclosed
US-8829014-B2 Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2014-09-09 US disclosed
EP-2007393-B1 THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS UNIV LOUISIANA STATE (US) 2013-08-21 EP disclosed
CN-101884629-B Controlled release preparation TAKEDA PHARMACEUTICAL 2013-08-21 CN disclosed
US-20120283268-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers GIORDANO ANTHONY (US) 2012-11-08 US disclosed
US-8217037-B2 Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2012-07-10 US disclosed
EP-2308492-A1 Process for preparing lansoprazole KRKA, tovarna zdravil, d.d., Novo mesto (SI) 2011-04-13 EP disclosed
EP-1838314-B1 PROCESS FOR PREPARING LANSOPRAZOLE KRKA TOVARNA ZDRAVIL D D NOVO (SI) 2010-07-28 EP disclosed
US-7662968-B2 Process for preparing lansoprazole KRKA tovarna zdravil, d.d.. (SI) 2010-02-16 US disclosed
US-7662968-B2 Process for preparing lansoprazole KRKA tovarna zdravil, d.d.. (SI) 2010-02-16 US disclosed
US-20090306073-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) 2009-12-10 US disclosed
US-20070259049-A1 Process for preparing lansoprazole KRKA, TOVARNA ZDRAVIL, D.D. 2007-11-08 US disclosed
US-20070259049-A1 Process for preparing lansoprazole KRKA, TOVARNA ZDRAVIL, D.D. 2007-11-08 US disclosed
EP-1368338-A4 METHOD OF PREPARING LANSOPRAZOLE AND ITS INTERMEDIATE HANSOL CHEMIENCE CO LTD (KR) 2004-09-15 EP disclosed
EP-1368338-A1 METHOD OF PREPARING LANSOPRAZOLE AND ITS INTERMEDIATE Chemtech Research Incorporation (KR) 2003-12-10 EP disclosed
WO-2002074766-A1 METHOD OF PREPARING LANSOPRAZOLE AND ITS INTERMEDIATE CHEMTECH RESEARCH INCORPORATION (KR) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259049-A1 Process for preparing lansoprazole CYP51A1, CYP2D6, CYP3A4 CYP17A1 836/4885SSTR4 264/4885GSK3B 3535/4885
US-20090306073-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers TPMT, TST, SSB CYP17A1 3266/4885SSTR4 1993/4885GSK3B 4203/4885
US-20120283268-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers TPMT, TST, SSB CYP17A1 3266/4885SSTR4 1993/4885GSK3B 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.